<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Bronchiectasis in adults: Treatment of acute and recurrent exacerbations
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Bronchiectasis in adults: Treatment of acute and recurrent exacerbations
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Bronchiectasis in adults: Treatment of acute and recurrent exacerbations
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan F Barker, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            James K Stoller, MD, MS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 11, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H3996504885">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bronchiectasis arises from chronic inflammation in the airways, leading to pathologic airway dilation and wall thickening. Clinically, this manifests with chronic cough and viscid daily sputum production as well as a propensity to develop recurrent upper airway infections, termed bronchiectasis exacerbations. Acute exacerbations stimulate ongoing neutrophilic airway inflammation, resulting in progressive lung damage, lung function decline, and worsened quality of life [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Multiple conditions may precipitate the development of bronchiectasis, but all require an initial infectious insult in combination with either impairments in airway drainage or defects in host defense. Of the multiple etiologies of bronchiectasis, only a few respond to direct treatment (eg, cystic fibrosis, certain immunodeficiencies, nontuberculous mycobacterial (NTM) infection, alpha-1 antitrypsin deficiency, and allergic bronchopulmonary aspergillosis). Instead, management of bronchiectasis is aimed primarily at treating exacerbations, controlling chronic infection and airway bleeding, reducing inflammation, and improving bronchial hygiene [
         <a href="#rid1">
          1,2
         </a>
         ]. Surgical resection of affected areas may also be useful in selected patients.
        </p>
        <p>
         The treatment of bronchiectasis exacerbations, including surgical options for refractory disease, will be reviewed here. The diagnosis and treatment of cystic fibrosis and the clinical manifestations, diagnosis, and chronic management of stable bronchiectasis in adults are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6367.html" rel="external">
          "Cystic fibrosis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">
          "Cystic fibrosis: Overview of the treatment of lung disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1444.html" rel="external">
          "Clinical manifestations and diagnosis of bronchiectasis in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/129310.html" rel="external">
          "Bronchiectasis in adults: Maintaining lung health"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3311038852">
         <span class="h1">
          DEFINITION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of an acute exacerbation is made exclusively by reported symptoms. Developed for research purposes (but useful in a clinical context as well), the consensus definition of bronchiectasis exacerbation is an acute clinical deterioration, requiring a change in therapy, manifesting with at least three of the following symptoms over ≥48 hours [
         <a href="#rid3">
          3
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cough
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sputum volume and/or consistency
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sputum purulence
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Breathlessness and/or exercise intolerance
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fatigue and/or malaise
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hemoptysis
        </p>
        <p>
        </p>
        <p>
         Implied within this definition is the exclusion of other causes of clinical deterioration, such as pneumonia, anemia, pulmonary embolism, or heart failure. Although antibiotic therapies can be similar, bronchiectasis exacerbations arise from acute on chronic infection of the airways (which can sometimes extend to the lung parenchyma), while pneumonias are caused by acute infection of the lung parenchyma. Evaluation and treatment of pneumonia is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/117561.html" rel="external">
          "Overview of community-acquired pneumonia in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3133.html" rel="external">
          "Pseudomonas aeruginosa pneumonia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2167823462">
         <span class="h1">
          RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most reliable predictor of future exacerbations is a prior history of exacerbations [
         <a href="#rid4">
          4
         </a>
         ]. Patients with chronic
         <em>
          Pseudomonas aeruginosa
         </em>
         infection also have greatly increased exacerbation risk [
         <a href="#rid5">
          5
         </a>
         ]. There is accumulating evidence that viral infections are important initial triggers of bronchiectasis exacerbations [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p>
         Among 1826 patients enrolled in the United States Bronchiectasis Research Registry, exacerbations were reported at baseline in 64 percent within the preceding two years [
         <a href="#rid8">
          8
         </a>
         ]. Some patients appear to be "frequent exacerbators," defined as having three or more exacerbations per year, while other patients have fewer exacerbations [
         <a href="#rid9">
          9
         </a>
         ]. In the nonintervention arm of one clinical trial, patients with bronchiectasis and a history of at least one exacerbation in the prior year developed an average of 1.6 exacerbations over the ensuing six months [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         In one analysis of 21 observational studies and over 3500 patients with bronchiectasis, patients with chronic
         <em>
          Pseudomonas
         </em>
         infection had an average of 1.0 additional exacerbations per year (95% CI, 0.6-1.3 exacerbations/year) and a more than six-fold increased risk of hospital admission (odds ratio [OR] 6.6, 95% CI 3.2-14) [
         <a href="#rid11">
          11
         </a>
         ] compared with the remainder of the cohort. In a separate cluster analysis of multiple European databases, chronic
         <em>
          Pseudomonas
         </em>
         infection defined a clinical phenotype that included increased inflammatory markers, more severe disease, lower quality of life, and increased risk of exacerbations [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Respiratory viral infections (eg, rhinovirus, influenza, and Epstein-Barr virus) may trigger exacerbations of bronchiectasis. Most studies are observational and demonstrate increased respiratory virus prevalence at times of exacerbations compared with steady state [
         <a href="#rid6">
          6
         </a>
         ]. Some studies also show increased inflammatory markers during virus-associated exacerbations, lending credence to a viral role in exacerbation pathogenesis.
        </p>
        <p>
         The role of respiratory viruses in triggering exacerbations of bronchiectasis is further supported by a prospective analysis of 147 patients from an international registry of bronchiectasis over the course of the coronavirus disease 2019 (COVID-19) pandemic [
         <a href="#rid7">
          7
         </a>
         ]. During the first year of the pandemic (March 2020 to March 2021), this cohort experienced an average of 1.1 exacerbations per year, compared with 2.1 and 2.0 exacerbations per year in the preceding two years [
         <a href="#rid7">
          7
         </a>
         ]. The percentage of patients with severe exacerbations requiring hospitalization was 9 percent in the pandemic year, compared with 14 and 16 percent previously. Only two patients suffered confirmed COVID-19 infections. A further retrospective cohort study of insurance databases confirmed reduced exacerbations during the first year of the pandemic in the United States [
         <a href="#rid12">
          12
         </a>
         ]. Social distancing measures (eg, stay-at-home orders, mask wearing, social distancing) with reduction in viral exposures likely contributed to this dramatic decline in exacerbations.
        </p>
        <p>
         Other risk factors are under investigation. Sputum neutrophil elastase is an emerging biomarker candidate that correlates with increased future exacerbation risk and antibiotic responsiveness, but testing is not yet widely available [
         <a href="#rid13">
          13,14
         </a>
         ]. Air pollution may also increase the risk of exacerbations, particularly ones in which a particular pathogen is not identified [
         <a href="#rid15">
          15
         </a>
         ]. One study has suggested that relative immunoglobulin G2 (IgG2) subclass deficiency may be associated with increased exacerbation risk [
         <a href="#rid16">
          16
         </a>
         ]. Patients with stable bronchiectasis and either high depression scores or a high symptom burden identified using validated questionnaires (Hospital Anxiety and Depression Scale [HADS] or Quality of Life Bronchiectasis Respiratory Symptom Scale [Qol-B-RSS], respectively) had an increased risk of an exacerbation in the ensuing year. [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H88749872">
         <span class="h1">
          PRESENTATION AND INITIAL EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with recurrent exacerbations have a recognizable change in respiratory and systemic symptoms that typify a new exacerbation. Evaluation of exacerbations is focused on excluding other causes of worsening symptoms and identifying the specific pathogen(s) involved.
        </p>
        <p class="headingAnchor" id="H2119630078">
         <span class="h2">
          Presenting symptoms and signs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute bacterial infections are usually heralded by increased production of sputum that is more viscous and darker in color than baseline. This altered sputum production may be accompanied by shortness of breath, pleuritic chest pain, or hemoptysis. Despite the infectious nature of the process, fever and chills are frequently absent; fatigue and malaise are common [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Lung examination may be normal or may reveal crackles, rhonchi, low-pitched or polyphonic wheezes, or midinspiratory squeaks. High-pitched expiratory wheezes may also be heard, particularly in patients with concomitant asthma or COPD.
        </p>
        <p class="headingAnchor" id="H667297659">
         <span class="h2">
          Identifying pathogens
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients presenting with an acute bronchiectasis exacerbation should have a Gram stain and sputum culture prior to antibiotic therapy. Prompt sputum culture helps identify the causal organism and allows adjustment of initial therapy based on antibiotic susceptibility. Because exacerbations of bronchiectasis can be triggered by respiratory viral infections, we send nasal secretions for influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing depending on local disease patterns.
        </p>
        <p>
         The bacterial flora in bronchiectasis is slightly different from that seen in chronic bronchitis. Frequently isolated pathogens include
         <em>
          Haemophilus influenzae
         </em>
         ,
         <em>
          Moraxella catarrhalis
         </em>
         ,
         <em>
          Staphylococcus aureus
         </em>
         ,
         <em>
          Pseudomonas aeruginosa
         </em>
         (especially mucoid types),
         <em>
          Stenotrophomonas maltophilia,
         </em>
         and, less frequently,
         <em>
          Streptococcus pneumoniae
         </em>
         [
         <a href="#rid19">
          19-21
         </a>
         ]. The likelihood of resistant organisms tends to increase with the number of prior courses of antibiotics.
        </p>
        <p class="headingAnchor" id="H2111855236">
         <span class="h2">
          Assessing for concomitant pneumonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Complaints of fever, chills, night sweats, or severe breathlessness should prompt a chest radiograph to evaluate for pneumonia. Bronchiectasis patients with pneumonia may notice more systemic symptoms or localized chest pain than they typically experience with other exacerbations.
        </p>
        <p>
         For patients with fever ≥38°C, tachypnea, tachycardia, hypotension, altered mental status, or respiratory distress, we assess resting and ambulatory oximetry, order a complete blood count and differential, and obtain routine chemistries including (blood urea nitrogen) BUN and creatinine to further assess exacerbation severity. Arterial blood gases may also be drawn when the presentation raises concern for respiratory failure (eg, respiratory distress, altered mental status). Most of these patients require initial inpatient management. (See
         <a class="local">
          'Defining severity and site of care'
         </a>
         below.)
        </p>
        <p>
         Treatment for pneumonia in bronchiectasis patients must consider the likelihood of resistant pathogens but otherwise adheres to standard treatment strategies. (See
         <a class="medical medical_review" href="/z/d/html/117561.html" rel="external">
          "Overview of community-acquired pneumonia in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3133.html" rel="external">
          "Pseudomonas aeruginosa pneumonia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1675531530">
         <span class="h1">
          MANAGEMENT OF INFECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mainstay of therapy for bronchiectasis exacerbations is antimicrobial treatment. Prompt management of acute infection with appropriately targeted therapies decreases inflammation and additional structural lung damage, thereby preventing disease progression. Optimal antibiotic selection and tailoring based on sensitivities allow control of exacerbations while minimizing the development of highly resistant pathogens.
        </p>
        <p class="headingAnchor" id="H3224935523">
         <span class="h2">
          Defining severity and site of care
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most acute exacerbations arise from low-grade infections of the upper airways that can be managed in the outpatient setting. However, certain high-risk features or practical considerations may prompt inpatient management. These include evidence of severe infection, concern for patient frailty, need for intravenous therapy, difficulties with adherence, active hemoptysis, and outpatient treatment failure  (
         <a class="graphic graphic_table graphicRef140902" href="/z/d/graphic/140902.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H216022140">
         <span class="h2">
          Approach to outpatient antibiotic therapy, for low-risk patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most afebrile, clinically stable patients with an exacerbation of bronchiectasis can be treated with an oral antibiotic. The initial antibiotic regimen for acute exacerbations of bronchiectasis is tailored to prior sputum cultures and sensitivities, when possible, rather than chosen empirically. Additional factors in antibiotic selection include determining whether to use oral or parenteral administration, the history of success or failure of prior regimens, and the presence of allergy or intolerance to antimicrobial agents. There is no role for inhaled antibiotics as sole agents during an acute exacerbation.
        </p>
        <p class="headingAnchor" id="H906657744">
         <span class="h3">
          Initial antibiotic selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial antibiotic selection is guided by any sputum culture results obtained within the past 12 to 24 months as well as prior patient experience.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          No recent sputum culture data available
         </strong>
         – For those without culture information, a fluoroquinolone (eg,
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         ) is a reasonable, broad spectrum therapeutic option.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Recent sputum culture with sensitive organisms
         </strong>
         – For patients whose sputum cultures do not show beta-lactamase-positive
         <em>
          H. influenzae
         </em>
         or
         <em>
          Pseudomonas
         </em>
         , reasonable initial antibiotic choices include either
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         500 mg three times daily or
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         100 mg twice daily based on typical colonization and local antibiotic resistance patterns. Alternatively, other antibiotics with a similar spectrum of coverage may be used. (See
         <a class="local">
          'Identifying pathogens'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Recent sputum culture with nonpseudomonal beta-lactamase-positive organism
         </strong>
         – In the presence of
         <em>
          Moraxella catarrhalis
         </em>
         or beta-lactamase producing
         <em>
          H. influenzae
         </em>
         , oral antibiotic choices include
         <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">
          amoxicillin-clavulanate
         </a>
         , a second or third generation cephalosporin,
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         , or a fluoroquinolone [
         <a href="#rid23">
          23
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/17122.html" rel="external">
          "
          <i>
           Moraxella catarrhalis
          </i>
          infections", section on 'Treatment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8048.html" rel="external">
          "Epidemiology, clinical manifestations, diagnosis, and treatment of
          <i>
           Haemophilus influenzae
          </i>
          ", section on 'Directed treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prior sputum-growing
         </strong>
         <strong>
          <em>
           Pseudomonas
          </em>
         </strong>
         – Regardless of antibiotic sensitivity,
         <em>
          Pseudomonas aeruginosa
         </em>
         infections are highly virulent and associated with a poor prognosis. The presence of sputum
         <em>
          Pseudomonas aeruginosa
         </em>
         is associated with increased death, exacerbations, and hospital admissions [
         <a href="#rid5">
          5,11,24,25
         </a>
         ]. Exacerbations in patients with chronic
         <em>
          Pseudomonas
         </em>
         infection should be treated aggressively with antibiotics based on known sensitivities alongside close monitoring to assess for treatment failure. Inhaled antibiotics have not been found to be useful in the setting of acute exacerbations.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the absence of known resistance to quinolones, the usual initial antibiotic choice is
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         , 500 to 750 mg twice daily [
         <a href="#rid23">
          23
         </a>
         ]. However, if the patient has had prior courses of ciprofloxacin, quinolone resistance often necessitates administration of intravenous antibiotics. Examples include
         <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">
          piperacillin-tazobactam
         </a>
         , a 4
         <sup>
          th
         </sup>
         generation cephalosporin (
         <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">
          cefepime
         </a>
         or
         <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">
          ceftazidime
         </a>
         ), an aminoglycoside (
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         favored, but never as monotherapy), a carbapenem (
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         or
         <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">
          imipenem
         </a>
         ), or
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Because of the propensity of
         <em>
          P. aeruginosa
         </em>
         to develop resistance and the limited availability of oral agents, the efficacy of adding inhaled
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         solution (TS) to oral
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         has been studied, but it has not been found to be helpful. For example, in one multicenter trial, 53 patients with known
         <em>
          P. aeruginosa
         </em>
         infection who were having exacerbations of bronchiectasis were randomly assigned to receive ciprofloxacin plus inhaled TS or ciprofloxacin plus placebo for two weeks [
         <a href="#rid26">
          26
         </a>
         ]. The addition of inhaled TS to ciprofloxacin did not improve clinical outcomes compared with ciprofloxacin alone, although there was a marked reduction in sputum
         <em>
          Pseudomonas
         </em>
         density in the TS plus ciprofloxacin group. Wheezing was more common with inhaled TS.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although current data do not suggest utility in the acute setting, certain aerosolized antibiotics may be helpful for exacerbation prophylaxis. (See
         <a class="medical medical_review" href="/z/d/html/129310.html" rel="external">
          "Bronchiectasis in adults: Maintaining lung health", section on 'Inhaled antibiotics'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2928059562">
         <span class="h3">
          Duration of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal duration of therapy is not well defined. Engaging patients in shared decision making surrounding acute treatment is important for maintaining a therapeutic alliance. For patients who rarely experience exacerbations, we agree with expert groups who favor a treatment duration of 10 to 14 days [
         <a href="#rid27">
          27,28
         </a>
         ]. Patients with more frequent exacerbations often form strongly held opinions regarding antibiotic therapy.
        </p>
        <p>
         European Respiratory Society (ERS) guidelines suggest a 14-day course of antibiotics based on expert consensus, although they note that shorter and longer durations have not been directly compared [
         <a href="#rid2">
          2
         </a>
         ]. The same guideline panel suggested that patients with mild symptoms, milder baseline disease, sensitive nonpseudomonal pathogens, or a rapid return to baseline state may benefit from shorter courses, although evidence to support this is lacking [
         <a href="#rid2">
          2
         </a>
         ]. These factors play a role in our shared decision making with patients.
        </p>
        <p class="headingAnchor" id="H3460663432">
         <span class="h3">
          Tailoring therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not usually tailor oral antibiotics to new sputum culture results if the patient is improving on their current regimen [
         <a href="#rid22">
          22
         </a>
         ]. For patients who are failing to improve, however, we switch to appropriate coverage for the newly isolated organisms. In addition, we generally narrow home intravenous regimens to the most effective and efficient therapies with the fewest side effects based on current susceptibilities.
        </p>
        <p class="headingAnchor" id="H508799474">
         <span class="h3">
          Assessing treatment failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most outpatients who receive effective antibiotic therapy notice some improvement in their symptoms within 72 hours. Failure to improve or worsening systemic symptoms (eg, fevers, chills, malaise) should prompt re-evaluation of therapy, including a repeat chest radiograph and sputum culture [
         <a href="#rid22">
          22
         </a>
         ]. In patients whose initial culture demonstrates suboptimal antibiotic selection based on the isolate, switching to an alternative outpatient regimen is reasonable if there are no new high-risk clinical features  (
         <a class="graphic graphic_table graphicRef140902" href="/z/d/graphic/140902.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Defining severity and site of care'
         </a>
         above.)
        </p>
        <p>
         For patients with new high-risk clinical features or without an explanation for treatment failure, we frequently transition to intravenous antibiotic therapy in a hospital. (See
         <a class="local">
          'Patients admitted after failed outpatient therapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1720701243">
         <span class="h2">
          Approach to inpatient therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients with acute bronchiectasis exacerbations requiring intravenous antibiotic therapy begin treatment in the hospital setting. Selection of antibiotic therapy otherwise depends on the indication for inpatient treatment  (
         <a class="graphic graphic_table graphicRef140902" href="/z/d/graphic/140902.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1416518645">
         <span class="h3">
          Patients with severe infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with bronchiectasis demonstrating evidence of severe infection, sepsis, or impending respiratory failure should receive broad-spectrum intravenous antibiotics covering both
         <em>
          Pseudomonas
         </em>
         and methicillin-resistant
         <em>
          Staphylococcus aureus
         </em>
         (MRSA) while awaiting culture data. Typical regimens use
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         or
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         for MRSA and an antipseudomonal penicillin, third generation cephalosporin, carbapenem, or
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         for
         <em>
          Pseudomonas
         </em>
         . Those with known chronic pseudomonal infection should receive antibiotics based on recent susceptibilities; we prefer up-front dual-agent therapy (eg, addition of a fluoroquinolone or aminoglycoside to one of the options listed above) pending culture results.
        </p>
        <p>
         Once the patient has stabilized and results of initial cultures are available, the antibiotic regimen can be narrowed to a sensitive antibiotic with the fewest side effects. For patients with resistant organisms such as
         <em>
          P. aeruginosa
         </em>
         or requiring intravenous antibiotics, we prefer a 14-day course [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3409021567">
         <span class="h3">
          Patients requiring intravenous antibiotics for resistant organisms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients without high-risk features who require intravenous antibiotic therapy for resistant organisms should be treated based on the culture data available, with therapy tailored based on any new culture results.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prior sputum culture with resistant
         </strong>
         <strong>
          <em>
           Pseudomonas
          </em>
         </strong>
         – For patients with known airway infection with
         <em>
          Pseudomonas
         </em>
         that is resistant to oral quinolones, the initial antibiotic choice is based on the sensitivity profile from culture data and history of allergy to antibiotics. (See
         <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">
          "Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Antibiotics with antipseudomonal activity'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         It is controversial whether single or dual (eg, beta-lactam plus aminoglycoside) antibiotic therapy is preferable for flares of bronchiectasis due to
         <em>
          Pseudomonas
         </em>
         [
         <a href="#rid22">
          22
         </a>
         ]. A meta-analysis of studies examining this question in patients with cystic fibrosis was unable to determine which course of therapy is better [
         <a href="#rid29">
          29
         </a>
         ]. We typically use a single agent (eg, antipseudomonal penicillin,
         <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">
          ceftazidime
         </a>
         , carbapenem, or
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         ) unless the patient appears acutely ill. (See
         <a class="local">
          'Patients with severe infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The questions of single versus dual therapy and antibiotic selection and dosing for
         <em>
          Pseudomonas
         </em>
         pneumonia are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3133.html" rel="external">
          "Pseudomonas aeruginosa pneumonia", section on 'Management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">
          "Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Role of combination antimicrobial therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Use of aminoglycoside antibiotics requires careful dosing and monitoring to avoid renal toxicity and ototoxicity. Aminoglycosides should never be used as single agents. (See
         <a class="medical medical_review" href="/z/d/html/475.html" rel="external">
          "Dosing and administration of parenteral aminoglycosides"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Recent sputum culture or other evidence of MRSA
         </strong>
         – In hospitalized patients with MRSA in prior sputum samples, Gram-positive cocci in clusters on a current sputum Gram stain or positive MRSA colonization on nasal screening, the initial empiric regimen should include
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         or
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         600 mg every 12 hours (off-label). Vancomycin should be dosed to achieve therapeutic levels. (See
         <a class="medical medical_review" href="/z/d/html/484.html" rel="external">
          "Vancomycin: Parenteral dosing, monitoring, and adverse effects in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In one study, multidrug resistant organisms were isolated in one-quarter of bronchiectasis exacerbations; of these, MRSA was the culprit organism in approximately 20 percent [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         After culture results from the current exacerbation return, antibiotics can be narrowed to a sensitive antibiotic with the fewest side effects. For patients with resistant organisms requiring continued intravenous antibiotics, we prefer a 14-day course [
         <a href="#rid23">
          23
         </a>
         ]. We engage in shared decision making regarding antibiotic duration for patients with mild disease or exacerbations who have returned to baseline and do not require continued intravenous therapy.
        </p>
        <p class="headingAnchor" id="H1022058329">
         <span class="h3">
          Patients admitted after failed outpatient therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach for patients admitted after failure of outpatient treatment depends on the local antibiotic resistance patterns, choice of outpatient antibiotics, and patient-specific culture data. For example, if the patient did not improve on an oral quinolone, coverage for resistant
         <em>
          Pseudomonas
         </em>
         and MRSA should be included, pending updated culture results. Care should be taken to avoid drugs in the same class as the ones that failed in the outpatient setting or antibiotics for which the patient has known resistant flora. Patients with available culture data showing new resistant organisms can be treated with antibiotics tailored to the new isolate. (See
         <a class="local">
          'Assessing treatment failure'
         </a>
         above and
         <a class="local">
          'Patients requiring intravenous antibiotics for resistant organisms'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1019734599">
         <span class="h3">
          Other patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with frailty, other practical difficulties with outpatient treatment, or hemoptysis  (
         <a class="graphic graphic_table graphicRef140902" href="/z/d/graphic/140902.html" rel="external">
          table 1
         </a>
         ), the approach to antibiotic therapy is generally the same as that used for outpatients, but it is accompanied by close monitoring to ensure adherence and assess clinical course. (See
         <a class="local">
          'Approach to outpatient antibiotic therapy, for low-risk patients'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2758465628">
         <span class="h2">
          Acute exacerbation due to influenza or COVID-19
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who present with an exacerbation that is caused by viral infection, we begin antiviral therapy. Failure to improve despite antiviral therapy should prompt antibiotic treatment based on sputum culture results, if available. (See
         <a class="local">
          'Approach to outpatient antibiotic therapy, for low-risk patients'
         </a>
         above.)
        </p>
        <p>
         Influenza antiviral therapy is usually indicated for patients whose exacerbation of bronchiectasis has been triggered by influenza virus, although the benefit of antiviral therapy wanes when more than 72 hours has transpired since symptom onset. The usual treatment is oral
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         or
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          baloxavir
         </a>
         ; intravenous
         <a class="drug drug_general" data-topicid="9527" href="/z/d/drug information/9527.html" rel="external">
          peramivir
         </a>
         can be used in patients who are unable to take oral medication. (See
         <a class="medical medical_review" href="/z/d/html/6998.html" rel="external">
          "Seasonal influenza in nonpregnant adults: Treatment"
         </a>
         .)
        </p>
        <p>
         According to the Centers for Disease Control and Prevention (CDC), patients with bronchiectasis are at increased risk for severe COVID-19  (
         <a class="graphic graphic_table graphicRef127477" href="/z/d/graphic/127477.html" rel="external">
          table 2
         </a>
         ). In general, patients with bronchiectasis exacerbations due to COVID-19 should receive antiviral therapies in either the outpatient or inpatient setting, depending on disease severity. Specific therapy for COVID-19 should be individualized based on symptoms, risk factors for severe disease, time since symptom onset, and location of care, as described separately. (See
         <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">
          "COVID-19: Management in hospitalized adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/139068.html" rel="external">
          "COVID-19: Management of adults with acute illness in the outpatient setting"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2612470272">
         <span class="h2">
          Enhanced airway clearance measures
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with exacerbations should maintain or increase their airway clearance regimen to facilitate expectoration of excess mucus and prevention of lung collapse. Most patients with bronchiectasis are recommended for mechanical positive expiratory pressure devices, chest physiotherapy, nebulized isotonic or hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         , or other therapeutic strategies to enhance airway clearance  (
         <a class="graphic graphic_table graphicRef78373" href="/z/d/graphic/78373.html" rel="external">
          table 3
         </a>
         ). During exacerbations, maintaining effective airway clearance prevents atelectasis and preserves blood flow (and hence antibiotic delivery) to affected lung tissue. A detailed discussion of airway clearance strategies in bronchiectasis may be found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/129310.html" rel="external">
          "Bronchiectasis in adults: Maintaining lung health", section on 'Airway clearance therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/129310.html" rel="external">
          "Bronchiectasis in adults: Maintaining lung health", section on 'Mucolytic agents and airway hydration'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H191192955">
         <span class="h1">
          MANAGEMENT OF EXACERBATION-ASSOCIATED HEMOPTYSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bleeding due to bronchiectasis is typically associated with acute infective episodes and is produced by injury to superficial mucosal neovascular bronchial arterioles. Although minor hemoptysis (blood-streaked sputum) is a frequent annoyance during exacerbations, more serious and even life-threatening bleeding may occur.
        </p>
        <p class="headingAnchor" id="H1860242591">
         <span class="h2">
          Assessing hemoptysis severity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hemoptysis severity is frequently defined in guidelines by volume of blood expectorated and the rate of bleeding; however, asking patients to make this assessment in the outpatient setting is very difficult. Blood is also often admixed with mucus, complicating quantification. When we ask patients about bleeding quantity, we try to refer to measuring cups rather than rely on abstract estimates. In general, we prefer a slightly less precise, but more patient-friendly, classification for help with triage:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Minimal
         </strong>
         – For patients with bronchiectasis exacerbations, hemoptysis where blood is mixed in with recognizable sputum is considered minimal. Small amounts of clot that are self-limited or occur less than twice a day also qualify.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Active
         </strong>
         – Active bleeding involves coughing up more than a teaspoon (5 mL) of clots or frank blood more than two or three times a day with bleeding ongoing for more than a few hours.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Life-threatening
         </strong>
         – This refers to hemoptysis that causes difficulty breathing or airway obstruction, significantly abnormal gas exchange (new hypoxemia or hypercarbia), or hemodynamic instability. Any large volume hemoptysis (eg, more than 100 mL/hour or more than 150 mL per day) should also be treated as potentially life-threatening. (See
         <a class="medical medical_review" href="/z/d/html/4394.html" rel="external">
          "Evaluation and management of life-threatening hemoptysis", section on 'Definition'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2565753382">
         <span class="h2">
          Minimal and self-limited hemoptysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         For bronchiectasis patients who present with blood in their sputum or self-limited expectoration of small amounts of blood during an exacerbation, we obtain a chest radiograph to assess for new cavitary processes or pneumonia complicating the exacerbation. For those with a stable chest radiograph, treatment of the exacerbation is generally sufficient, with further evaluation only necessary for clinical worsening. Those with new imaging findings generally require chest computed tomography (CT) to better delineate risk of further bleeding and need for additional treatment.
        </p>
        <p class="headingAnchor" id="H3270566563">
         <span class="h2">
          Active hemoptysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         For bronchiectasis patients with active bleeding, flexible bronchoscopy and chest CT with arterial contrast are complementary diagnostic tools to localize the bleeding to a lobe or segment. Once the site of bleeding is identified, local bronchoscopic techniques such as balloon tamponade, topical application of a vasoconstrictive or coagulant agent, laser therapy, electrocautery, argon plasma coagulation, and cryotherapy may be able to greatly decrease or stop the bleeding [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         If bronchoscopic techniques to control bleeding are unsuccessful or are not available, the next step is usually arteriographic embolization of bleeding sites (typically from a bronchial artery) by an interventional radiology (IR) service. If embolization is unsuccessful and bleeding persists, surgical resection may be necessary [
         <a href="#rid32">
          32
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4394.html" rel="external">
          "Evaluation and management of life-threatening hemoptysis", section on 'Initial investigations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1823925250">
         <span class="h2">
          Life-threatening hemoptysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with life-threatening hemoptysis, initial measures should focus on securing the airway, maintaining adequate ventilation, ensuring hemodynamic stability, and correcting any bleeding diathesis. Early bronchoscopy to identify the site of bleeding is very helpful for optimal positioning (placing the bleeding side down) and lung isolation if necessary. IR-guided techniques may be used subsequently in an attempt to achieve bleeding control. (See
         <a class="medical medical_review" href="/z/d/html/4394.html" rel="external">
          "Evaluation and management of life-threatening hemoptysis", section on 'Initial life-saving and supportive measures'
         </a>
         and
         <a class="local">
          'Active hemoptysis'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4394.html" rel="external">
          "Evaluation and management of life-threatening hemoptysis", section on 'Initial investigations'
         </a>
         .)
        </p>
        <p>
         Patients may occasionally require urgent surgery for the management of life-threatening hemoptysis due to bronchiectasis that cannot be controlled with less invasive measures. The evaluation and management of continuing active hemoptysis is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4394.html" rel="external">
          "Evaluation and management of life-threatening hemoptysis", section on 'Continued or recurrent life-threatening bleeding'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1359547045">
         <span class="h1">
          ADDITIONAL THERAPIES, IN CERTAIN POPULATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Additional therapies for bronchiectasis exacerbation may be warranted based on the etiology of bronchiectasis, pathogen involved, or presence of comorbid disease.
        </p>
        <p class="headingAnchor" id="H2958439014">
         <span class="h2">
          Nontuberculous mycobacterial infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         While nontuberculous mycobacterial (NTM) infection can be an opportunistic infection in patients with bronchiectasis, it can also be a primary cause of bronchiectasis [
         <a href="#rid8">
          8,33,34
         </a>
         ].
         <em>
          Mycobacterium. avium,
         </em>
         <em>
          M. intracellulare,
         </em>
         and
         <em>
          M. abscessus
         </em>
         are the most frequently isolated NTM and are responsible for the greatest clinical impact. Treating exacerbations arising from progressive mycobacterial disease as routine bronchiectasis exacerbations may lead to mycobacterial antibiotic resistance and complicate future efforts at eradication. The diagnosis and treatment of mycobacterial disease are described separately. (See
         <a class="medical medical_review" href="/z/d/html/5342.html" rel="external">
          "Overview of nontuberculous mycobacterial infections"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5343.html" rel="external">
          "Microbiology of nontuberculous mycobacteria"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5341.html" rel="external">
          "Treatment of
          <i>
           Mycobacterium avium
          </i>
          complex pulmonary infection in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1568610326">
         <span class="h2">
          ABPA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Allergic bronchopulmonary aspergillosis (ABPA) is classically a cause of central bronchiectasis in patients with asthma and can also arise in patients with bronchiectasis. While acute exacerbations may be due to bacteria and should be treated appropriately, definitive treatment of ABPA involves reducing allergic inflammation and aspergillus colonization (eg, with systemic glucocorticoids, antifungal agents, and/or
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         ) to limit progressive lung injury. Treatment of ABPA is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/104431.html" rel="external">
          "Treatment of allergic bronchopulmonary aspergillosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2532211722">
         <span class="h2">
          Patients receiving immunoglobulin therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain primary immunodeficiencies, such as common variable immunodeficiency, can be treated with
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         , intravenously (IVIG) or subcutaneously (SCIG). Patients with these conditions who have missed doses or are otherwise IgG deficient during a bronchiectasis exacerbation may benefit from receiving immune globulin treatment, although this has not been formally studied. Treatment is usually delayed for a few days after initiation of antibiotic therapy to prevent adverse reactions. The use of immunoglobulin preparations in primary immunodeficiencies is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3911.html" rel="external">
          "Immune globulin therapy in inborn errors of immunity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2967528903">
         <span class="h2">
          Comorbid COPD or asthma
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend the use of oral glucocorticoids or inhaled glucocorticoids (aka, inhaled corticosteroids [ICS]) only in patients with bronchiectasis exacerbations who have comorbid asthma or chronic obstructive pulmonary disease (COPD).
        </p>
        <p>
         Oral glucocorticoid bursts should be reserved for patients with comorbid asthma or COPD who have new or worsening wheezing that does not improve with airway clearance or a change in dyspnea. For patients with an acute exacerbation without these features, systemic glucocorticoids are avoided because they depress host immunity, promote bacterial and fungal colonization, and may perpetuate infection. Oral glucocorticoids also have other significant adverse effects that are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/528.html" rel="external">
          "Acute exacerbations of asthma in adults: Home and office management", section on 'Initiation of oral glucocorticoids'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1461.html" rel="external">
          "COPD exacerbations: Management", section on 'Home oral glucocorticoid therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         .)
        </p>
        <p>
         We do not generally alter chronic ICS therapy during bronchiectasis exacerbations in patients with asthma or COPD. The best available evidence suggests benefits to treating eosinophilic inflammation in asthma and COPD. Furthermore, the use of ICS does not appear to increase the risk of pneumonia in patients with concomitant bronchiectasis and COPD [
         <a href="#rid35">
          35
         </a>
         ]. Patients with persistent asthma should receive ICS as a controller medication, with up-titration and addition of other bronchodilators based on symptom control. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recommend ICS therapy in COPD based on exacerbation history and the presence of eosinophilic inflammation. (See
         <a class="medical medical_review" href="/z/d/html/547.html" rel="external">
          "An overview of asthma management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/90904.html" rel="external">
          "Asthma in children younger than 12 years: Overview of initiating therapy and monitoring control"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/122160.html" rel="external">
          "Stable COPD: Follow-up pharmacologic management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/540.html" rel="external">
          "Major side effects of inhaled glucocorticoids", section on 'Lung infection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4162242553">
         <span class="h1">
          OUTCOMES AFTER EXACERBATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although recovery to baseline is common after most acute exacerbations, frequent exacerbations portend a poor prognosis. Symptoms of a bronchiectasis exacerbation last for a median of 16 days, but approximately 16 percent of patients do not recover to baseline for at least one month [
         <a href="#rid36">
          36
         </a>
         ]. In some patients, exacerbations lead to irreversible morbidity. Patients with three or more exacerbations per year have twice the mortality rate of those who do not experience exacerbations (hazard ratio 2.0; 95% CI 1.0–4.0), even after accounting for many potential confounding factors [
         <a href="#rid4">
          4
         </a>
         ]. Similarly, exacerbations requiring hospital admission more than double the subsequent mortality risk [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3398995336">
         <span class="h1">
          PREVENTATIVE MEASURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based on the risk of clinical worsening and death associated with frequent exacerbations, much of the routine care of bronchiectasis patients is targeted at exacerbation prevention. These strategies are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/129310.html" rel="external">
          "Bronchiectasis in adults: Maintaining lung health"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3429670907">
         <span class="h1">
          MANAGEMENT OF REFRACTORY AND RECURRENT EXACERBATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients continue to have debilitating exacerbations and worsening lung function despite preventative measures. For those with localized disease, surgical resection may improve outcomes. Those with widespread bronchiectasis may be eligible for bilateral lung transplantation, but typical wait times remain long. Several promising experimental strategies to reduce exacerbations are under active investigation.
        </p>
        <p class="headingAnchor" id="H3464359806">
         <span class="h2">
          Surgical resection, in localized bronchiectasis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goal of surgical extirpation includes removal of the most involved segments or lobes while preserving the remaining lung. Middle and lower lobe resections are most often performed. The superior segment of the lower lobe may be involved to a lesser extent and can frequently be salvaged during lower lobe resection. At the same time, surgical resection should be complete, as residual disease left after resection has demonstrated worse outcomes in some studies [
         <a href="#rid23">
          23,37
         </a>
         ].
        </p>
        <p>
         Although empiric data are lacking, surgical intervention is usually combined with an aggressive perioperative antibiotic and bronchial hygiene regimen to reduce bacterial infection and improve drainage.
        </p>
        <p class="headingAnchor" id="H3914254483">
         <span class="h3">
          Patient selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, resectional surgery is considered for disease confined to one or two lobes that is not controlled by medical therapy and results in frequent infectious episodes. Examples of disease settings where resection might be favorable include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Removal of destroyed lung distal to partial obstruction by a nonmetastatic tumor or the residue of a foreign body
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recurrent infective episodes due to localized bronchiectasis not responsive to medical therapy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Overwhelming purulent and viscid sputum production in patients with localized bronchiectasis that is unresponsive to medical therapy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of a localized bronchiectatic area suspected of harboring resistant organisms such as nontuberculous mycobacteria (NTM) [
         <a href="#rid38">
          38,39
         </a>
         ] or multidrug-resistant tuberculosis (see
         <a class="medical medical_review" href="/z/d/html/5341.html" rel="external">
          "Treatment of
          <i>
           Mycobacterium avium
          </i>
          complex pulmonary infection in adults", section on 'Surgical management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8028.html" rel="external">
          "Treatment of drug-resistant pulmonary tuberculosis in adults"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Relative contraindications include untreatable progressive etiologies of bronchiectasis (eg, primary ciliary dyskinesia, recurrent aspiration), severe lung function abnormalities, anorexia, poor exertional tolerance, or other evidence of frailty. Preoperative pulmonary rehabilitation and nutritional interventions are helpful in improving the surgical fitness of some patients [
         <a href="#rid2">
          2,23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H826863759">
         <span class="h3">
          Outcomes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Overall, surgical outcomes are favorable in the select group of patients receiving surgical resection. Surgical case series have shown low 30-day mortality (&lt;2 percent) and resolution or improvement of symptoms in the majority of patients [
         <a href="#rid32">
          32,40-44
         </a>
         ]. The following studies illustrate typical reports:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the largest study from the past two decades, 790 patients (mean age 47 years) were followed for a mean of four years following lung resection (segmentectomy, lobectomy, pneumonectomy) [
         <a href="#rid41">
          41
         </a>
         ]. Mortality at 30 days was 1.1 percent. Seventy-five percent of patients became asymptomatic or were improved, while 15 percent were unimproved or worse.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another large case series, 134 patients (mean age 48 years) were followed for a mean of six years [
         <a href="#rid32">
          32
         </a>
         ]. Thirty-day mortality was 2 percent and 89 percent of patients improved.
        </p>
        <p>
        </p>
        <p>
         Postoperative complications include empyema, hemorrhage, prolonged air leak, and poorly expanding lung due to persistent atelectasis or suppuration. In selected patients, video-assisted thoracoscopic surgery (VATS) segmentectomy or lobectomy may allow fewer complications and shorter hospitalizations than thoracotomy. However, the presence of pleural adhesions may require conversion to an open procedure [
         <a href="#rid23">
          23,42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2466535739">
         <span class="h2">
          Lung transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         After bilateral orthotopic lung transplantation, the survival advantage gained by patients with bronchiectasis is comparable with that seen in other diagnostic groups, including cystic fibrosis [
         <a href="#rid45">
          45,46
         </a>
         ]. According to the Organ Procurement and Transplant Network (OPTN) database maintained by the United Network for Organ Sharing (UNOS), 407 patients with noncystic fibrosis bronchiectasis underwent lung transplantation in the United States between 1992 and 2019 [
         <a href="#rid47">
          47
         </a>
         ]. The mean age was 47 years, and the median transplant list waiting time was 254 days. The median survival time posttransplant was 5.5 to 6.0 years. Poor lung function (forced expiratory volume in one second [FEV
         <sub>
          1
         </sub>
         ] &lt;30 percent), severe secondary pulmonary hypertension, recurrent massive hemoptysis, or intensive care unit (ICU) admissions requiring noninvasive or invasive ventilation are among the indications for transplant referral [
         <a href="#rid23">
          23
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4659.html" rel="external">
          "Lung transplantation: An overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4658.html" rel="external">
          "Lung transplantation: General guidelines for recipient selection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H120586531">
         <span class="h2">
          Experimental approaches
         </span>
         <span class="headingEndMark">
          —
         </span>
         Experts from the United States [
         <a href="#rid48">
          48
         </a>
         ] and Europe [
         <a href="#rid49">
          49,50
         </a>
         ] have suggested that research priorities in bronchiectasis should include epidemiology, pathogenesis, and management [
         <a href="#rid49">
          49
         </a>
         ]. Active areas of research on management and prevention of refractory exacerbations include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Investigative methods for palliation of
         </strong>
         <strong>
          <em>
           P. aeruginosa
          </em>
         </strong>
         <strong>
          infection
         </strong>
         – Some patients with bronchiectasis have excess IgG2 specific to the bacterial O-antigen, which (unlike other antibodies) inhibits immune killing of
         <em>
          P. aeruginosa
         </em>
         in serum samples. One study examined the impact of treatment targeting these antibodies in two patients with bronchiectasis, severe respiratory insufficiency,
         <em>
          P. aeruginosa
         </em>
         airway infection, and elevated IgG2 serum levels [
         <a href="#rid51">
          51
         </a>
         ]. Plasmapheresis sessions followed by intravenous pooled
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         infusions for five days markedly improved patient clinical status by reducing time spent in the hospital and days on intravenous antibiotics over the next 8 to 12 months. Cultures for
         <em>
          P. aeruginosa
         </em>
         remained negative for three months, IgG2 levels were lowered, and ability to kill
         <em>
          P. aeruginosa
         </em>
         was improved.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Elastase inhibitors
         </strong>
         – Excess activation of neutrophil serine proteases (NSPs) is thought to contribute to perpetuation of inflammation and lung destruction in bronchiectasis, raising the possibility that an inhibitor of NSP activation (eg, brensocatib; INS1007) might reduce the rate of exacerbations. In a phase 2 trial (WILLOW), 256 participants who had at least two exacerbations in the prior year were treated with brensocatib 10 mg daily, brensocatib 25 mg daily, or placebo for 24 weeks [
         <a href="#rid52">
          52
         </a>
         ]. Over the course of the trial, 42 exacerbations occurred in the 25 mg brensocatib group, 34 in the 10 mg brensocatib group, and 54 in the placebo group. The time to first exacerbation was prolonged with brensocatib compared with placebo (adjusted hazard ratio approximately 0.6 in both groups, 95% CI 0.35-0.99). Overall, brensocatib was reportedly well tolerated; headache and dyspnea were common side effects that occurred more often in the 25 mg group than with placebo, but the numbers were small.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment based on eosinophilic endotype
         </strong>
         – Multiple studies are investigating differential treatment of patients with bronchiectasis who demonstrate eosinophilic inflammation. In a post-hoc analysis of a placebo-controlled trial examining inhaled
         <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">
          fluticasone
         </a>
         in obstructive lung diseases, patients with bronchiectasis and elevated blood eosinophils who received fluticasone demonstrated improved respiratory qualities of life [
         <a href="#rid53">
          53
         </a>
         ]. In a separate observational study, 21 patients with bronchiectasis underwent a trial of anti-eosinophilic biologic therapy based on peripheral eosinophilia &gt;300 cells/microL and refractory exacerbations despite aggressive management [
         <a href="#rid54">
          54
         </a>
         ]. Twelve patients received an interleukin (IL)-5 antagonist (
         <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">
          mepolizumab
         </a>
         ) and nine received an IL-5-alpha receptor antagonist (
         <a class="drug drug_general" data-topicid="115768" href="/z/d/drug information/115768.html" rel="external">
          benralizumab
         </a>
         ). After six months of therapy, there were significant improvements in FEV
         <sub>
          1
         </sub>
         and respiratory quality of life, as well as a trend towards reduced exacerbation frequency, compared with pretreatment assessment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Microbiome assessment
         </strong>
         – Culture-independent microbial gene surveys of airway secretions from individuals with noncystic fibrosis bronchiectasis have identified a broader array of microbial species, including anaerobic bacteria, that are not identified by routine culture [
         <a href="#rid55">
          55
         </a>
         ] and can remain relatively stable over long periods of time [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In studies of the airway microbiome, greater bacterial diversity is associated with better clinical parameters, including a higher FEV
         <sub>
          1
         </sub>
         and fewer symptoms, suggesting that low diversity may reflect overgrowth by pathogenic bacteria such as
         <em>
          P. aeruginosa
         </em>
         [
         <a href="#rid57">
          57
         </a>
         ]. Moreover, the clustering of organisms, particularly in association with
         <em>
          Pseudomonas
         </em>
         , correlates with exacerbations of bronchiectasis [
         <a href="#rid58">
          58
         </a>
         ]. Antibiotic treatment reduces this clustering or the so-called interactome [
         <a href="#rid59">
          59
         </a>
         ]. There may also be significant interaction between the airway and gut microbiome, with airway
         <em>
          Pseudomonas
         </em>
         interactions with gut
         <em>
          Bacteroides
         </em>
         and
         <em>
          Saccharomyces
         </em>
         correlating with increased exacerbations and greater radiologic and overall bronchiectasis severity [
         <a href="#rid60">
          60
         </a>
         ]. Use of this technology does not yet have clinical applicability.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Enhancing treatment adherence
         </strong>
         – Bronchiectasis is a complex chronic disease that often involves following a difficult and cumbersome management plan with multiple oral and nebulized medications and bronchial hygiene maneuvers throughout the day. Many of the treatments for bronchiectasis involve the use of off-label and expensive medications, prolonged administration time, and sometimes distressing adverse effects. Adherence to treatments involves patient-specific and treatment-related constraints. A pilot study involving a structured interview process has begun to explore factors to enhance treatment adherence among patients with bronchiectasis [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H742917476">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116208.html" rel="external">
          "Society guideline links: Bronchiectasis"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/122199.html" rel="external">
          "Society guideline links: Primary ciliary dyskinesia"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/118986.html" rel="external">
          "Society guideline links: Hemoptysis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24984600">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/86554.html" rel="external">
          "Patient education: Bronchiectasis in adults (The Basics)"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/16905.html" rel="external">
          "Patient education: Coughing up blood (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition and risk factors
         </strong>
         – Bronchiectasis exacerbations are usually caused by acute bacterial airway infection and are characterized by worsening of cough and sputum volume or purulence. Patients with a history of exacerbations or chronic pseudomonal infection are at the highest risk. (See
         <a class="local">
          'Definition'
         </a>
         above and
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         – Evaluation is focused on excluding other causes and identifying the specific pathogen(s) involved. Complaints of fever, chills, or night sweats prompt evaluation for pneumonia. Sputum Gram stain and culture should be obtained prior to antibiotic administration. (See
         <a class="local">
          'Presentation and initial evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of infection
         </strong>
         – Most acute exacerbations can be managed in the outpatient setting. However, evidence of severe infection, concern for patient frailty, need for intravenous therapy, difficulties with adherence, active hemoptysis, or outpatient treatment failure may prompt inpatient management  (
         <a class="graphic graphic_table graphicRef140902" href="/z/d/graphic/140902.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Defining severity and site of care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Airway clearance
         </strong>
         – All patients with exacerbations should maintain or increase their airway clearance regimen to facilitate sputum removal and prevent lung collapse.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antiviral therapy
         </strong>
         – Influenza or COVID-19 antiviral therapy is usually indicated for bronchiectasis exacerbations due to these viruses, although the benefit of antiviral therapy wanes with time since symptom onset. (See
         <a class="local">
          'Acute exacerbation due to influenza or COVID-19'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Empiric antibiotic therapy
         </strong>
         – The initial antibiotic regimen for acute exacerbations of bronchiectasis is tailored to prior sputum cultures and sensitivities, when available. Additional factors in antibiotic selection include oral versus parenteral administration, the history of success or failure of prior regimens, and patient drug allergies. (See
         <a class="local">
          'Approach to outpatient antibiotic therapy, for low-risk patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          No recent sputum data
         </strong>
         – For clinically stable patients without sputum culture data over the past 12 to 24 months or known prior colonization with resistant organisms, we suggest initiation of a fluoroquinolone antibiotic (eg,
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         ) rather than an alternative oral antibiotic (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Initial antibiotic selection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         For patients with bronchiectasis hospitalized for severe infection or respiratory distress, we suggest broad spectrum empiric therapy with coverage of both methicillin-resistant
         <em>
          Staphylococcus aureus
         </em>
         (MRSA) (eg,
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         or
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         ) and
         <em>
          Pseudomonas
         </em>
         (eg, antipseudomonal penicillin, third generation cephalosporin, a carbapenem, or
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         ) rather than narrower regimens (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Patients with severe infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Recent cultures without highly resistant organisms
         </strong>
         – For clinically stable patients with sputum cultures from the past 6 to 12 months that do not reveal antibiotic-resistant organisms, we suggest
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         500 mg three times daily or
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         100 mg twice daily rather than other agents (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). In the presence of beta-lactamase producing organisms, choices include
         <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">
          amoxicillin-clavulanate
         </a>
         , second or third generation cephalosporin, doxycycline, or a fluoroquinolone. Sensitive isolates of
         <em>
          Pseudomonas
         </em>
         can be treated with
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         . (See
         <a class="local">
          'Initial antibiotic selection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Recent cultures with highly resistant organisms
         </strong>
         – For clinically stable patients with the most recent prior cultures growing chronic
         <em>
          Pseudomonas aeruginosa
         </em>
         or MRSA resistant to oral agents, we suggest initiation of an intravenous antibiotic with efficacy against prior isolates (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Initial antibiotic selection'
         </a>
         above and
         <a class="local">
          'Patients requiring intravenous antibiotics for resistant organisms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         For patients with a history of chronic
         <em>
          Pseudomonas
         </em>
         infection who are hospitalized for severe infection or respiratory distress, we suggest empiric therapy with
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         or
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         and two antipseudomonal antibiotics rather than vancomycin or linezolid and only one antipseudomonal antibiotic (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Approach to inpatient therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Course of therapy
         </strong>
         – Patients who do not improve or who are on intravenous therapy should be transitioned to antibiotics tailored to sputum cultures from the current exacerbation once these are available. We typically treat acute exacerbations for 10 to 14 days. (See
         <a class="local">
          'Duration of therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemoptysis
         </strong>
         – Patients with active hemoptysis should receive chest CT and bronchoscopy to help localize and treat the site of bleeding. For patients with brisk or life-threatening hemoptysis, bronchial artery embolization or resectional surgery may be required. (See
         <a class="local">
          'Management of exacerbation-associated hemoptysis'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4394.html" rel="external">
          "Evaluation and management of life-threatening hemoptysis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Refractory disease
         </strong>
         – For patients with bronchiectasis confined to one or two lobes that is not controlled by medical therapy, we suggest surgical evaluation rather than continued medical therapy alone (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). In diffuse disease refractory to medical management, referral for lung transplantation may be appropriate. (See
         <a class="local">
          'Management of refractory and recurrent exacerbations'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Choi H, Chalmers JD. Bronchiectasis exacerbation: a narrative review of causes, risk factors, management and prevention. Ann Transl Med 2023; 11:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J 2017; 50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hill AT, Haworth CS, Aliberti S, et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J 2017; 49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med 2014; 189:576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aliberti S, Lonni S, Dore S, et al. Clinical phenotypes in adult patients with bronchiectasis. Eur Respir J 2016; 47:1113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kartsiouni E, Chatzipanagiotou S, Tamvakeras P, Douros K. The role of viral infections in pulmonary exacerbations of patients with non-cystic fibrosis bronchiectasis: A systematic review. Respir Investig 2022; 60:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crichton ML, Shoemark A, Chalmers JD. The Impact of the COVID-19 Pandemic on Exacerbations and Symptoms in Bronchiectasis: A Prospective Study. Am J Respir Crit Care Med 2021; 204:857.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aksamit TR, O'Donnell AE, Barker A, et al. Adult Patients With Bronchiectasis: A First Look at the US Bronchiectasis Research Registry. Chest 2017; 151:982.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amati F, Simonetta E, Gramegna A, et al. The biology of pulmonary exacerbations in bronchiectasis. Eur Respir Rev 2019; 28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 380:660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finch S, McDonnell MJ, Abo-Leyah H, et al. A Comprehensive Analysis of the Impact of Pseudomonas aeruginosa Colonization on Prognosis in Adult Bronchiectasis. Ann Am Thorac Soc 2015; 12:1602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Åstrand A, Kiddle SJ, Siva Ganesh Mudedla R, et al. Effect of COVID-19 on Bronchiectasis Exacerbation Rates: A Retrospective US Insurance Claims Study. Ann Am Thorac Soc 2023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chalmers JD, Moffitt KL, Suarez-Cuartin G, et al. Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis. Am J Respir Crit Care Med 2017; 195:1384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shoemark A, Cant E, Carreto L, et al. A point-of-care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and risk of exacerbation. Eur Respir J 2019; 53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goeminne PC, Cox B, Finch S, et al. The impact of acute air pollution fluctuations on bronchiectasis pulmonary exacerbation: a case-crossover analysis. Eur Respir J 2018; 52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang Y, Clarke A, Regan KH, et al. Isolated IgG2 deficiency is an independent risk factor for exacerbations in bronchiectasis. QJM 2022; 115:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gao YH, Zheng HZ, Lu HW, et al. The impact of depression and anxiety on the risk of exacerbation in adults with bronchiectasis: A prospective cohort study. Eur Respir J 2023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gao YH, Zheng HZ, Lu HW, et al. Quality of Life Bronchiectasis Respiratory Symptom Predicts the Risk of Exacerbations in Adults with Bronchiectasis: A Prospective Observational Study. Ann Am Thorac Soc 2023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000; 162:1277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Angrill J, Agustí C, de Celis R, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002; 57:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metersky ML, Choate R, Aksamit TR, et al. Stenotrophomonas maltophilia in patients with bronchiectasis: An analysis of the US bronchiectasis and NTM Research Registry. Respir Med 2022; 193:106746.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasteur MC, Bilton D, Hill AT, British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65 Suppl 1:i1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hill AT, Sullivan AL, Chalmers JD, et al. British Thoracic Society Guideline for bronchiectasis in adults. Thorax 2019; 74:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Araújo D, Shteinberg M, Aliberti S, et al. The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis. Eur Respir J 2018; 51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curran CS, Bolig T, Torabi-Parizi P. Mechanisms and Targeted Therapies for Pseudomonas aeruginosa Lung Infection. Am J Respir Crit Care Med 2018; 197:708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bilton D, Henig N, Morrissey B, Gotfried M. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006; 130:1503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Judson MA, Chaudhry H, Compa DR, OʼDonnell AE. A Delphi study of pharmacotherapy for noncystic fibrosis bronchiectasis. Am J Med Sci 2014; 348:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang AB, Bell SC, Torzillo PJ, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines. Med J Aust 2015; 202:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elphick HE, Tan A. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. Cochrane Database Syst Rev 2005; :CD002007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menéndez R, Méndez R, Polverino E, et al. Risk factors for multidrug-resistant pathogens in bronchiectasis exacerbations. BMC Infect Dis 2017; 17:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davidson K, Shojaee S. Managing Massive Hemoptysis. Chest 2020; 157:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agasthian T, Deschamps C, Trastek VF, et al. Surgical management of bronchiectasis. Ann Thorac Surg 1996; 62:976.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henkle E, Chan B, Curtis JR, et al. Characteristics and Health-care Utilization History of Patients With Bronchiectasis in US Medicare Enrollees With Prescription Drug Plans, 2006 to 2014. Chest 2018; 154:1311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goeminne PC, Scheers H, Decraene A, et al. Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients. Respir Res 2012; 13:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ritchie AI, Singayagam A, Mitchell S, et al. The Effect of Inhaled Corticosteroids on Pneumonia Risk in Patients With COPD-Bronchiectasis Overlap: A UK Population-Based Case-Control Study. Chest 2023; 164:875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brill SE, Patel AR, Singh R, et al. Lung function, symptoms and inflammation during exacerbations of non-cystic fibrosis bronchiectasis: a prospective observational cohort study. Respir Res 2015; 16:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneiter D, Meyer N, Lardinois D, et al. Surgery for non-localized bronchiectasis. Br J Surg 2005; 92:836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ku JH, Siegel SAR, Philley J, et al. Outcomes of Resectional Thoracic Surgery for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease in 105 Patients in the United States. Chest 2022; 161:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim JY, Lee HW, Yim JJ, Kwak N. Outcomes of Adjunctive Surgery in Patients With Nontuberculous Mycobacterial Pulmonary Disease: A Systematic Review and Meta-analysis. Chest 2023; 163:763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newall C, Stockley RA, Hill SL. Exercise training and inspiratory muscle training in patients with bronchiectasis. Thorax 2005; 60:943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang P, Jiang G, Ding J, et al. Surgical treatment of bronchiectasis: a retrospective analysis of 790 patients. Ann Thorac Surg 2010; 90:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell JD, Yu JA, Bishop A, et al. Thoracoscopic lobectomy and segmentectomy for infectious lung disease. Ann Thorac Surg 2012; 93:1033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balkanli K, Genç O, Dakak M, et al. Surgical management of bronchiectasis: analysis and short-term results in 238 patients. Eur J Cardiothorac Surg 2003; 24:699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vallilo CC, Terra RM, de Albuquerque AL, et al. Lung resection improves the quality of life of patients with symptomatic bronchiectasis. Ann Thorac Surg 2014; 98:1034.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rademacher J, Ringshausen FC, Suhling H, et al. Lung transplantation for non-cystic fibrosis bronchiectasis. Respir Med 2016; 115:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rusanov V, Fridman V, Wille K, Kramer MR. Lung Transplantation for Cystic Fibrosis and Non-cystic Fibrosis Bronchiectasis: A Single-Center Experience. Transplant Proc 2019; 51:2029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jung F, Riley L, Lascano J. Outcomes and survival following lung transplantation in non-cystic fibrosis bronchiectasis. ERJ Open Res 2022; 8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henkle E, Aksamit TR, Daley CL, et al. US Patient-Centered Research Priorities and Roadmap for Bronchiectasis. Chest 2018; 154:1016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aliberti S, Masefield S, Polverino E, et al. Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration. Eur Respir J 2016; 48:632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chalmers JD, Aliberti S, Altenburg J, et al. Transforming clinical research and science in bronchiectasis: EMBARC3, a European Respiratory Society Clinical Research Collaboration. Eur Respir J 2023; 61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wells TJ, Davison J, Sheehan E, et al. The Use of Plasmapheresis in Patients with Bronchiectasis with Pseudomonas aeruginosa Infection and Inhibitory Antibodies. Am J Respir Crit Care Med 2017; 195:955.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chalmers JD, Haworth CS, Metersky ML, et al. Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. N Engl J Med 2020; 383:2127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aliberti S, Sotgiu G, Blasi F, et al. Blood eosinophils predict inhaled fluticasone response in bronchiectasis. Eur Respir J 2020; 56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rademacher J, Konwert S, Fuge J, et al. Anti-IL5 and anti-IL5Rα therapy for clinically significant bronchiectasis with eosinophilic endotype: a case series. Eur Respir J 2020; 55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richardson H, Dicker AJ, Barclay H, Chalmers JD. The microbiome in bronchiectasis. Eur Respir Rev 2019; 28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woo TE, Lim R, Heirali AA, et al. A longitudinal characterization of the Non-Cystic Fibrosis Bronchiectasis airway microbiome. Sci Rep 2019; 9:6871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tunney MM, Einarsson GG, Wei L, et al. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med 2013; 187:1118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi H, Ryu S, Keir HR, et al. Inflammatory Molecular Endotypes in Bronchiectasis: A European Multicenter Cohort Study. Am J Respir Crit Care Med 2023; 208:1166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mac Aogáin M, Narayana JK, Tiew PY, et al. Integrative microbiomics in bronchiectasis exacerbations. Nat Med 2021; 27:688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Narayana JK, Aliberti S, Mac Aogáin M, et al. Microbial Dysregulation of the Gut-Lung Axis in Bronchiectasis. Am J Respir Crit Care Med 2023; 207:908.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCullough AR, Ryan C, O'Neill B, et al. Defining the content and delivery of an intervention to Change AdhereNce to treatment in BonchiEctasis (CAN-BE): a qualitative approach incorporating the Theoretical Domains Framework, behavioural change techniques and stakeholder expert panels. BMC Health Serv Res 2015; 15:342.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1435 Version 70.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36760239" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Bronchiectasis exacerbation: a narrative review of causes, risk factors, management and prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28889110" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : European Respiratory Society guidelines for the management of adult bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28596426" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24328736" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The bronchiectasis severity index. An international derivation and validation study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26846833" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Clinical phenotypes in adult patients with bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35811289" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The role of viral infections in pulmonary exacerbations of patients with non-cystic fibrosis bronchiectasis: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34265234" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The Impact of the COVID-19 Pandemic on Exacerbations and Symptoms in Bronchiectasis: A Prospective Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27889361" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Adult Patients With Bronchiectasis: A First Look at the US Bronchiectasis Research Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31748420" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The biology of pulmonary exacerbations in bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22901887" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26356317" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : A Comprehensive Analysis of the Impact of Pseudomonas aeruginosa Colonization on Prognosis in Adult Bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37962905" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Effect of COVID-19 on Bronchiectasis Exacerbation Rates: A Retrospective US Insurance Claims Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27911604" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31151955" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : A point-of-care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and risk of exacerbation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29903857" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The impact of acute air pollution fluctuations on bronchiectasis pulmonary exacerbation: a case-crossover analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33970283" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Isolated IgG2 deficiency is an independent risk factor for exacerbations in bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36669778" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The impact of depression and anxiety on the risk of exacerbation in adults with bronchiectasis: A prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37962906" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Quality of Life Bronchiectasis Respiratory Symptom Predicts the Risk of Exacerbations in Adults with Bronchiectasis: A Prospective Observational Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11029331" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : An investigation into causative factors in patients with bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11809984" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35124355" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Stenotrophomonas maltophilia in patients with bronchiectasis: An analysis of the US bronchiectasis and NTM Research Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20627931" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : British Thoracic Society guideline for non-CF bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30545985" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : British Thoracic Society Guideline for bronchiectasis in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29386336" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29087211" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Mechanisms and Targeted Therapies for Pseudomonas aeruginosa Lung Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17099030" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24992394" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : A Delphi study of pharmacotherapy for noncystic fibrosis bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25588439" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15846627" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Single versus combination intravenous antibiotic therapy for people with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28964261" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Risk factors for multidrug-resistant pathogens in bronchiectasis exacerbations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31374211" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Managing Massive Hemoptysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8823075" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Surgical management of bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30055168" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Characteristics and Health-care Utilization History of Patients With Bronchiectasis in US Medicare Enrollees With Prescription Drug Plans, 2006 to 2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22423975" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37419145" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The Effect of Inhaled Corticosteroids on Pneumonia Risk in Patients With COPD-Bronchiectasis Overlap: A UK Population-Based Case-Control Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25849856" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Lung function, symptoms and inflammation during exacerbations of non-cystic fibrosis bronchiectasis: a prospective observational cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15898122" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Surgery for non-localized bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34390707" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Outcomes of Resectional Thoracic Surgery for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease in 105 Patients in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36208713" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Outcomes of Adjunctive Surgery in Patients With Nontuberculous Mycobacterial Pulmonary Disease: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15994254" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Exercise training and inspiratory muscle training in patients with bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20609785" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Surgical treatment of bronchiectasis: a retrospective analysis of 790 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22386091" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Thoracoscopic lobectomy and segmentectomy for infectious lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14583301" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Surgical management of bronchiectasis: analysis and short-term results in 238 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24928672" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Lung resection improves the quality of life of patients with symptomatic bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27215505" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Lung transplantation for non-cystic fibrosis bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31303417" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Lung Transplantation for Cystic Fibrosis and Non-cystic Fibrosis Bronchiectasis: A Single-Center Experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35174245" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Outcomes and survival following lung transplantation in non-cystic fibrosis bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29981718" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : US Patient-Centered Research Priorities and Roadmap for Bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27288031" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37385653" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Transforming clinical research and science in bronchiectasis: EMBARC3, a European Respiratory Society Clinical Research Collaboration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28362198" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : The Use of Plasmapheresis in Patients with Bronchiectasis with Pseudomonas aeruginosa Infection and Inhibitory Antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32897034" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32398295" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Blood eosinophils predict inhaled fluticasone response in bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31619477" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Anti-IL5 and anti-IL5Rαtherapy for clinically significant bronchiectasis with eosinophilic endotype: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31484665" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : The microbiome in bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31053725" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : A longitudinal characterization of the Non-Cystic Fibrosis Bronchiectasis airway microbiome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23348972" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37769155" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Inflammatory Molecular Endotypes in Bronchiectasis: A European Multicenter Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33820995" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Integrative microbiomics in bronchiectasis exacerbations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36288294" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Microbial Dysregulation of the Gut-Lung Axis in Bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26297038" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Defining the content and delivery of an intervention to Change AdhereNce to treatment in BonchiEctasis (CAN-BE): a qualitative approach incorporating the Theoretical Domains Framework, behavioural change techniques and stakeholder expert panels.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
